L5a Pharmacology 3

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/45

encourage image

There's no tags or description

Looks like no tags are added yet.

46 Terms

1
New cards

Selective Estrogen Receptor Modulators (SERMs)


  • Estrogen receptor ligands that act like estrogens in some tissues but antagonize estrogen action in other tissues

  • Antagonistic activity is used to treat certain hormone sensitive tumors (e.g., breast cancer)


2
New cards

Tamoxifen AND toremifene antagonist and agonist activity

  •  Estrogen ANTAGONIST on breast tissue (so tx breast cancer)

  • Estrogen AGONIST on bone, cholesterol metabolism, endometrium, coagulation

    system

    • agonist on Bone - inc bone mineral density

    • endometrium → endometrial cancer


3
New cards

tamoxifene toxicity and associated monitoring

due to hormonal changes

  • Hot flashes, mood changes, vaginal bleeding

    • monitor for abnormal vaginal bleeding/discharge

other

  • cataracts

  • thromboembolism (DVT, stroke, PE)

    • monitor: s/s of VTE

    • CI: DVT/PE

again: endometrial hyperplasia/cancer


4
New cards

Tamoxifene DI

  • 2D6 inhibitor - dec tamoxifen efficacy

  • 2C9 inhibitor - avoid concurrent use w/ warfarin cuz will lead to excess anticoagulant effect


5
New cards

Tamoxifen 2D6 drug interaction mechanism

  • what drug to avoid

  • what is the alternative


knowt flashcard image
6
New cards

Tamoxifen CI

DVT/PE, concurrent warfarin therapy

7
New cards

Toremifene toxicity and asociated monitoring

Unique: QT prolongation

  • monitor: electrolytes (Mg, K, Ca), ECG/EKG

rest similar to tamoxifene except no cataract

due to hormonal changes

  • hot flashes, vaginal discharge

    • monitor: abnormal vaginal bleeding/discharges

other

  • thromboembolism,

    • monitor: s/s VTE

  • endometrial hyperplasia/cancer


8
New cards

toremifene CI

related to QT

  • congenital/acquired QT prolongation

  • uncorrected HoK, HoMg


9
New cards

Raloxifene MOA

  • Estrogen ANTAGONIST on breast tissue and endometrium — NO ENDO cancer

  • Estrogen AGONIST on bone, cholesterol metabolism, coagulation system

    • same as other SERM except endometrium is antagonized


10
New cards

Raloxifene toxicity and associated monitoring

  • Unique: higher DVT/PE, inc risk of death due to stroke

    • monitor: s/s of VTE

  • flu-like symptoms,

due to hormone

  • hot flashes, arthralgia/myalgias (no vaginal discharge)


11
New cards

Raloxifene CI

  • DVT/PE

  • Pregnancy (THE ONLY ONE OUT OF 3 CI)


12
New cards

Selective Estrogen Receptor Down regulator (SERD) MOA and indication


MOA: Competitively binds to estrogen receptors (ER) on tumors and other tissue targets, producing a nuclear complex that causes a down-regulation of ERs; this results in inhibition of tumor growth

  • No estrogenic effects

Drug: fulvestrant

13
New cards

Fulvestrant toxicity and associated monitoring

  • even though no hormonal changes: Hot flashes, athralgias/myalgias

  • inc LFTs,

    • monitor: LFTs

  • injection site pain, hematoma/bleeding (from injection)

    • Monitor: s/s of bleeding

Monitor: pregnancy test (rmbr: raloxifene is CI w/ Pregnancy)

14
New cards

Aromatase inhibitor MoA

  • Aromatase converts androgens (androstenedione and testosterone) to estradiol (estrogen)

  • Inhibiting aromatase decreases production of estradiol

    • Can only be used in postmenopausal women


15
New cards

what one is REversible, nonsteroidal; and IRREversible, steroidal AI?

Reversible, non-steroidal

  • anastrozle

  • letrozole

IRReversible, steroidal

  • exemestane


<p>Reversible, non-steroidal</p><ul><li><p><span style="color: blue;">anastrozle</span></p></li><li><p><span style="color: blue;">letrozole</span></p></li></ul><p>IRReversible, steroidal</p><ul><li><p><span style="color: blue;">exemestane</span></p></li></ul><p></p>
16
New cards

AI class toxicity and it’s monitoring

UNIQUE (extra effect due to hormonal changes):

  • dec bone mineral density → osteoporosis, fractures (take ca++, vit/D or biphosphonates)

    • monitor: DEXA scans, serum Ca++, vit D levels

hormonal changes:

  • Hot flashes, arthralgias/myalgias, sexual dysfunction

other

  • inc LFTs

    • monitor: liver function

  • inc cholesterol

    • monitor: lipid profile



17
New cards

AI class CI

  • premenopausal women

  • pregnancy (rmbr: fulvestrant, raloxifene)


18
New cards

nonsteroidal anti-androgen MOA

  • first gen

  • 2nd gen


  • 1st generation:

    • Binds to androgen receptors and competitively blocks testosterone from binding

  • 2nd generation:

    • In addition to above:

    • Inhibits androgen receptor nuclear translocation and DNA transcription → apoptosis


19
New cards

common toxicity for nilutamide and bicalutamide and its associated monitoring

  • hepatotoxicity

    • monitor: LFTs

  • loss of glycemic control. bicalutamide is specifically in pt w/ diabetes, nilutamide did not specify

    • monitor: blood glucose


20
New cards

Nilutamide additional toxicity and its monitoring

  • UNIQUE: Night blindness (25-40%)

  • interstitial pnuemontitis

    • Monitor: chest X-ray

  • alcohol intolerance


21
New cards

Bicalutamide addtional toxicity and monitoring

  • Unique: QTC prolongation (rmbr: toremixifene)

    • monitor: ECG

  • dec bone density


22
New cards

2nd gen (enzalutamide, apalutamide, darolutamide) class toxicity and its monitoring parameter

  • Imp: CV events, seizures

    • monitor: s/s of IHD and seizures

    • note: doralutamide seizure risk not as high compared to enzalutamide and apalutamide cuz not cross BBB

Due to hormonal

  • hot flashes, gynecomastia, dec libido, impotence (note: we are in men now)

note: no additional toxicity for Darolutamide

23
New cards

enzalutamide additional toxicity and its monitoring parameter

  • fractures

Monitoring parameter unrelated to toxicity

  • CBC

  • LFT

  • BP


24
New cards

Apalutamide additional toxicity and its monitoring parameter

  • Unique: dermatologic toxicity, QTC (rmbr Bicalutamide, toremifene)

    • monitor: dermatologic toxicity, EKG/ECG

  • Hypothyroidism

    • Monitor: TSH

  • Fracture (was also in enzalutamide)


25
New cards

2nd gen Androgen antagonist drug interaction

  • enzalutamide

  • apalutamide

  • darolutamide



All 3 → CYP3A4 substrate

  • Enza + Apa → Strong 3A4 inducer, 2C19 inducer

  • Enza + Apa → CYP2C8 substrate

  • enza only: 2c9 inducer

  • Daro → P-gp substrate


26
New cards

steroial anti -androgen (abiraterone) MOA

  • Selectively and irreversibly inhibits CYP17

  • Inhibits formation of testosterone precursors– dehydroepiandrosterone (DHEA) and androstenedione

  • dec DHT, dec cortisol, inc aldosterone

    • Abiraterone → Blocks CYP17 → ↓ Cortisol → ↑ ACTH → ↑ Mineralocorticoids (aka adrenal insufficiency)

    • that is why you co-administer steroid to prevent inc ACTH


<ul><li><p>Selectively and irreversibly inhibits<span style="color: blue;"> CYP17</span></p></li><li><p><span style="color: blue;">Inhibits formation of testosterone precursors– dehydroepiandrosterone (DHEA) and androstenedione</span></p></li><li><p><span style="color: blue;">dec DHT, dec cortisol, inc aldosterone </span></p><ul><li><p>Abiraterone → Blocks CYP17 → ↓ Cortisol → ↑ ACTH → ↑ Mineralocorticoids (aka adrenal insufficiency)</p></li><li><p>that is why you <span style="color: blue;">co-administer steroid to prevent inc ACTH</span></p></li></ul></li></ul><p></p>
27
New cards

Abirasterone must be given with:

steroid: prednisone or methylprednisolone

28
New cards

abiraterone PK: absorption and DDI

  • Absorption:

    • Zytiga® only: empty stomach.: Taking with food causes unpredictable absorption that may be as high as 10x if taken without food.

  • Substrate of CYP3A4 – drug-drug interactions with inhibitors or inducers


29
New cards

abiraterone toxicity and monitoring

  • Unique: adrenal insufficiency and compensatory mineralocorticoid excess (hoK, Joint swelling/edema, HTN) - MUST BE CO-administered w/ corticosteroid

    • monitor: s/s of Adrenal insufficiency, electrolyte, fluid status, BP

  • Hepatotoxicity (rmbr 1st gen: nil and bicalutamide)

    • monitor: LFT

  • Hot flashes


30
New cards

GnRH normal physiology

knowt flashcard image
31
New cards

GnRH receptor agonist and antagonists MOA

GnRH antagonist onset is faster than GnRH agonist

<p>GnRH antagonist onset is faster than GnRH agonist</p>
32
New cards
<p>Just read, no back</p>

Just read, no back

33
New cards

Tumor flare in prostate cancer w/ GnRH AGONist

can lead to various symptoms and even oncologic emergencies

  • if worry, use GnRH antagonist


<p>can lead to various symptoms and even oncologic emergencies</p><ul><li><p>if worry, use GnRH antagonist</p></li></ul><p></p>
34
New cards

GnRH agonist and antagonist class toxicity and shared AE and monitor

  • dec bone mineral density, osteoporosis - Ca++ and Vit D supplement

    • monitor: bone mineral density (get a baseline)

Metabolic Effect

  • hyperglycemia (new-onset diabetes),

    • Monitor: blood glucose

  • CAD, MI, QTC prolongation (rmbr apalutamide, Bicalutamide, toremifene)

    • monitor: ECG/EKG

Other due to hormonal

  • hot flashes, dec libido, emotional lability/depression

Tumor flare: only with AGONist

  • monitor: spinal cord compression, urinary tract obstruction


35
New cards
  • GnRH agonist female and male additional specific toxicity

  • GnRH antagonist male ONLY toxicity — not used in Female


  • Female: vaginal dryness, amenorrhea

  • Male: impotence, gynecomastia


36
New cards

Proteasome inhibitor MOA

  • general

  • Bortezomib

  • carfilzomib


Both lead to cell cycle arrest and apoptosis

  • Bortezomib: Reversibly inhibit 26S proteosome

  • Carfilzomib: IRReversibly inhibit 20S proteosome (proteolytic core w/in the 26S proteosome)


<p>Both lead to cell cycle arrest and apoptosis</p><ul><li><p>Bortezomib: <span style="color: blue;">Reversibly inhibit 26S proteosome </span></p></li><li><p>Carfilzomib:<span style="color: blue;"> IRReversibly</span> inhibit <span style="color: blue;">20S proteosome (proteolytic core w/in the 26S proteosome)</span></p></li></ul><p></p>
37
New cards

bortezomib and carfilzomib shared AE and monitoring

  • supportive care


  • myelosuppression

    • Monitor: CBC

  • hepatotoxicity

    • Monitor: LFTs (dose adjustment)

  • herpes reactivation

    • SUPPORTIVE care: Antiviral prophylaxis


38
New cards

Bortezomib addtional toxicity and monitoring

  • Uniue: peripheral neuropathy (SQ <<< IV)

    • monitor: signs of peripheral neuropathy


39
New cards

Carfilzomib toxicity and monitoring

Unique:

  • CV events (HF, Pulmonary Edema, MI)

  • Infusion-related rxn

  • renal toxicity

Monitor: BP, s/s of infusion-related rxn, SCr


40
New cards

IMiD toxicity

  • Unique: Teratogenicity (REM), Thromboembolism, 2nd meliganancy

    • monitor: pregnancy test, s/s VTE

    • VTE so severe that need VTE prophylaxis for supportive care

  • myelosuppression, Heptotoxicity

    • Monitor: CBC, LFT

  • Peripheral neuropathy (thalidomide » lenalidomide/pomalidomide)

  • dermatologic rxn


41
New cards

which IMiD has DDI (only 1)?

pomalidomide - 1A2

  • smoking may induce metabolism and dec efficacy


42
New cards
<p>Just read, no back</p>

Just read, no back

no back

43
New cards
<p>Just read</p>

Just read

no back

44
New cards

Asparaginase (Pegaspargase) product MOA

knowt flashcard image
45
New cards

Pagaspargase toxicity and its monitoring parameter

  • unique:

    • coagulopathies (hemorrhage and thrombosis) - VTE prophylaxis can be used if platelet count is adequate but need close monitoring)

      • monitor: coagulation parameter, S/S VTE

    • Pancreatitis

      • monitor: amlyase/lipase

  • HyperTGC, hyperglycemia

    • monitor: TGC, blood glucose

  • hypersensitivity - cutaneous rxn, edema, hoTN, SOB, respiratory collapse

  • hepatotoxicity

    • monitor: LFT


46
New cards

Pegaspargase supportive care

knowt flashcard image